Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13137657 | 0.83 | KMT2A (0.55) | KMT2AMEN1RAB9ANPC1GFER | |
| SCHEMBL10498609 | 0.77 | LMNA (0.51) | KMT2AMEN1RAB9ANPC1GFER | |
| SCHEMBL15928331 | 0.77 | NPY5R (0.61) | KMT2AMEN1RAB9ANPC1GFER | |
| SCHEMBL19173201 | 0.76 | RXFP1 (0.72) | KMT2AMEN1RAB9ANPC1GFER | |
| SCHEMBL11089709 | 0.76 | LMNA (0.49) | KMT2AMEN1RAB9ANPC1GFER | |
| SCHEMBL7454467 | 0.76 | KMT2A (0.72) | KMT2AMEN1RAB9ANPC1GFER | |
| SCHEMBL15800700 | 0.76 | KMT2A (0.72) | KMT2AMEN1RAB9ANPC1GFER | |
| SCHEMBL13900720 | 0.75 | NPC1 (0.47) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL9435378 | 0.75 | CNR1 (0.56) | KMT2AMEN1RAB9ANPC1MAPT | |
| Hydrochloric Acid SCHEMBL9038264 | 0.74 | KMT2A (0.70) | KMT2AMEN1RAB9ANPC1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237705-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | PETERSON JOHN R (US) | 2013-09-12 | — | — | US | disclosed |
| US-8431699-B2 | Method for manufacture of 2-oxoimidazolidines | Vertichem Corporation (CA) | 2013-04-30 | — | — | US | disclosed |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | THESIS CHEMISTRY, LLC (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237705-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | ODC1, NISCH, IMPDH2 | KMT2A 2171/4885MEN1 1188/4885RAB9A 3064/4885 |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | ODC1, CBR3, CBR1 | KMT2A 1520/4885MEN1 1630/4885RAB9A 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.